West Branch Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

West Branch Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$994	Hold	2	–	–	﹤0.01%	303
2026 Q1	$894	Hold	2	–	–	﹤0.01%	320
2025 Q4	$907	Hold	2	–	–	﹤0.01%	356
2025 Q3	$784	Hold	2	–	–	﹤0.01%	388
2025 Q2	$891	Hold	2	–	–	﹤0.01%	400
2025 Q1	$970	Hold	2	–	–	﹤0.01%	418
2024 Q4	$806	Hold	2	–	–	﹤0.01%	407
2024 Q3	$931	Buy	+2	New	+$961	﹤0.01%	390
2022 Q1	–	Sell	-40	Closed	-$9K	–	467
2021 Q4	$9K	Hold	40	–	–	﹤0.01%	340
2021 Q3	$7K	Hold	40	–	–	﹤0.01%	337
2021 Q2	$8K	Buy	+40	New	+$8.37K	﹤0.01%	345

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

West Branch Capital's VRTX Position: Q2 2026 in Review

West Branch Capital held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 2 shares worth $994. The position accounts for ﹤0.01% of the portfolio, ranked #303.

West Branch Capital first reported a position in VRTX in Q2 2021 and has held it in 11 quarters since. The position peaked at $9K in Q4 2021. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

West Branch Capital held 2 shares of Vertex Pharmaceuticals worth $994 as of Q2 2026.
West Branch Capital left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up ﹤0.01% of West Branch Capital's portfolio in Q2 2026, its #303 holding.
West Branch Capital first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 11 quarters since.
West Branch Capital's Vertex Pharmaceuticals position peaked at $9K in Q4 2021.
334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on West Branch Capital's 13F filing for Q2 2026, filed 10 Jul 2026.